ReviewInflammation and regeneration2022
Controlling skin microbiome as a new bacteriotherapy for inflammatory skin diseases.
Review in Inflammation and regeneration, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Current insights and trends in atopic dermatitis and microbiota interactions: a systematic review and bibliometric analysis.Frontiers in microbiology · 2025Pooled it
- Antimicrobial Peptides of the Skin: Roles in Skin Cancer and Clinical Applications.Experimental dermatology · 2026Review
- The Anti-inflammatory, Antioxidant Effects and Protective Barrier Function of Cell-Free Supernatant of Potential Probiotic Staphylococcus epidermidis CCSM0322 in HaCaT Cell Induced by UVB.Probiotics and antimicrobial proteins · 2026Article
- Integrated Machine Learning and Structure-Based Virtual Screening Identifies Natural Product Targeting 50S Ribosome Inhibitory Activity AgainstMolecules (Basel, Switzerland) · 2025Article
- Topical administration of mupirocin ointment and fusidic acid in bacterial infection-induced skin diseases.Postepy dermatologii i alergologii · 2025Article
- From 1D microbiological assays to 3D advanced skin models: enhancing preclinical strategies to unravel the impact of bioactive textiles on the human skin microbiome.Frontiers in cellular and infection microbiology · 2025Review
- Amplicon-based analysis reveals link between adolescent acne and altered facial skin microbiome induced by negative emotional states.Frontiers in cellular and infection microbiology · 2025Article
- Dermatological Health in the Light of Skin Microbiome Evolution.Journal of cosmetic dermatology · 2024Review
- In utero or early-in-life exposure to antibiotics and the risk of childhood atopic dermatitis, a population-based cohort study.The British journal of dermatology · 2024Article
- TargetingPharmaceutics · 2024Article
- Highly active probiotic hydrogels matrixed on bacterial EPS accelerate wound healing via maintaining stable skin microbiota and reducing inflammation.Bioactive materials · 2024Article
- Transcriptomic analysis of lipoteichoic acid‑treated undifferentiated and neutrophil‑like differentiated HL‑60 cells.Experimental and therapeutic medicine · 2024Article
- Emerging Multiscale Biofabrication Approaches for Bacteriotherapy.Molecules (Basel, Switzerland) · 2024Review
- Causal roles of skin and gut microbiota in skin appendage disorders suggested by genetic study.Frontiers in immunology · 2024Article
- Causal roles of skin microbiota in skin cancers suggested by genetic study.Frontiers in microbiology · 2024Article
- Review
- Microbiota and IL-33/31 Axis Linkage: Implications and Therapeutic Perspectives in Atopic Dermatitis and Psoriasis.Biomolecules · 2023Review
- The Role and Benefits of Dermocosmetics in Acne Management in Japan.Dermatology and therapy · 2023Review
- The Skin Microbiome: Current Techniques, Challenges, and Future Directions.Microorganisms · 2023Review
- A Wall Fragment ofPharmaceutics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The skin serves as the interface between the human body and the environment and interacts with the microbial community. The skin microbiota consists of microorganisms, such as bacteria, fungi, mites, and viruses, and they fluctuate depending on the microenvironment defined by anatomical location and physiological function. The balance of interactions between the host and microbiota plays a pivotal role in the orchestration of skin homeostasis; however, the disturbance of the balance due to an alteration in the microbial communities, namely, dysbiosis, leads to various skin disorders. Recent developments in sequencing technology have provided new insights into the structure and function of skin microbial communities. Based on high-throughput sequencing analysis, a growing body of evidence indicates that a new treatment using live bacteria, termed bacteriotherapy, is a feasible therapeutic option for cutaneous diseases caused by dysbiosis. In particular, the administration of specific bacterial strains has been investigated as an exclusionary treatment strategy against pathogens associated with chronic skin disorders, whereas the safety, efficacy, and sustainability of this therapeutic approach using isolated live bacteria need to be further explored. In this review, we summarize our current understanding of the skin microbiota, as well as therapeutic strategies using characterized strains of live bacteria for skin inflammatory diseases. The ecosystem formed by interactions between the host and skin microbial consortium is still largely unexplored; however, advances in our understanding of the function of the skin microbiota at the strain level will lead to the development of new therapeutic methods.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.